HARVARD BIOSCIENCE INC (HBIO)
US4169061052 - Common Stock
Taking everything into account, HBIO scores 4 out of 10 in our fundamental rating. HBIO was compared to 58 industry peers in the Life Sciences Tools & Services industry. While HBIO is still in line with the averages on profitability rating, there are concerns on its financial health. HBIO is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
HBIO had positive earnings in the past year.
HBIO had a positive operating cash flow in the past year.
In the past 5 years HBIO always reported negative net income.
In the past 5 years HBIO always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.49%, HBIO is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
HBIO has a Return On Equity of -4.68%. This is in the better half of the industry: HBIO outperforms 63.79% of its industry peers.
HBIO's Return On Invested Capital of 1.36% is fine compared to the rest of the industry. HBIO outperforms 67.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.49% | ||
| ROE | -4.68% | ||
| ROIC | 1.36% |
ROA(3y)-3.07%
ROA(5y)-3.41%
ROE(3y)-6.06%
ROE(5y)-6.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of HBIO (1.69%) is better than 65.52% of its industry peers.
In the last couple of years the Operating Margin of HBIO has declined.
HBIO has a better Gross Margin (58.86%) than 77.59% of its industry peers.
In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.69% | ||
| PM (TTM) | N/A | ||
| GM | 58.86% |
OM growth 3Y118.22%
OM growth 5Y-12.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.35%
GM growth 5Y1.29%
2. Health
2.1 Basic Checks
HBIO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, HBIO has more shares outstanding
The number of shares outstanding for HBIO has been increased compared to 5 years ago.
HBIO has a better debt/assets ratio than last year.
2.2 Solvency
HBIO has an Altman-Z score of 1.12. This is a bad value and indicates that HBIO is not financially healthy and even has some risk of bankruptcy.
HBIO's Altman-Z score of 1.12 is on the low side compared to the rest of the industry. HBIO is outperformed by 63.79% of its industry peers.
The Debt to FCF ratio of HBIO is 3.12, which is a good value as it means it would take HBIO, 3.12 years of fcf income to pay off all of its debts.
HBIO has a Debt to FCF ratio of 3.12. This is amongst the best in the industry. HBIO outperforms 84.48% of its industry peers.
HBIO has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.42, HBIO is not doing good in the industry: 67.24% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 3.12 | ||
| Altman-Z | 1.12 |
ROIC/WACC0.11
WACC12.52%
2.3 Liquidity
HBIO has a Current Ratio of 1.85. This is a normal value and indicates that HBIO is financially healthy and should not expect problems in meeting its short term obligations.
HBIO has a Current ratio of 1.85. This is in the lower half of the industry: HBIO underperforms 67.24% of its industry peers.
HBIO has a Quick Ratio of 1.85. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of HBIO (0.92) is worse than 91.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 0.92 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
The Earnings Per Share has been decreasing by -6.51% on average over the past years.
HBIO shows a decrease in Revenue. In the last year, the revenue decreased by -0.96%.
The Revenue has been decreasing by -1.46% on average over the past years.
EPS 1Y (TTM)25%
EPS 3Y-2.13%
EPS 5Y-6.51%
EPS growth Q2Q0%
Revenue 1Y (TTM)-0.96%
Revenue growth 3Y3.21%
Revenue growth 5Y-1.46%
Revenue growth Q2Q-0.97%
3.2 Future
The Earnings Per Share is expected to grow by 36.01% on average over the next years. This is a very strong growth
Based on estimates for the next years, HBIO will show a small growth in Revenue. The Revenue will grow by 7.35% on average per year.
EPS Next Y42.8%
EPS Next 2Y40.43%
EPS Next 3Y36.01%
EPS Next 5YN/A
Revenue Next Year1.49%
Revenue Next 2Y5.32%
Revenue Next 3Y7.35%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.67, HBIO can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of HBIO indicates a rather cheap valuation: HBIO is cheaper than 86.21% of the companies listed in the same industry.
HBIO is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.28, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 17.97, HBIO is valued on the expensive side.
HBIO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HBIO is cheaper than 96.55% of the companies in the same industry.
HBIO's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 20.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.67 | ||
| Fwd PE | 17.97 |
4.2 Price Multiples
HBIO's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. HBIO is cheaper than 79.31% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HBIO is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.27 | ||
| EV/EBITDA | 22.26 |
4.3 Compensation for Growth
HBIO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HBIO's earnings are expected to grow with 36.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.6
PEG (5Y)N/A
EPS Next 2Y40.43%
EPS Next 3Y36.01%
5. Dividend
5.1 Amount
HBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HARVARD BIOSCIENCE INC
NASDAQ:HBIO (5/3/2024, 7:00:01 PM)
After market: 3.85 0 (0%)3.85
+0.03 (+0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap167.17M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.67 | ||
| Fwd PE | 17.97 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.6
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.49% | ||
| ROE | -4.68% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 1.69% | ||
| PM (TTM) | N/A | ||
| GM | 58.86% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.85 | ||
| Quick Ratio | 0.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)25%
EPS 3Y-2.13%
EPS 5Y
EPS growth Q2Q
EPS Next Y42.8%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-0.96%
Revenue growth 3Y3.21%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y